Chinese biotechnology company Immunochina Pharmaceuticals has raised a RMB$140 million (US$20.4 million) series C round of financing led by a syndicate of Chinese and international investors, according to a statement released on January 22.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 3 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription for $359
Enjoy comprehensive and exclusive data you can't find elsewhere!Subscribe for $359
Already have an account or paid subscription?